Review anchor
Melanin-concentrating hormone receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Melanin-concentrating hormone receptor 1
CHEMBL344
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Melanin-concentrating hormone receptor 1 as ChEMBL target CHEMBL344, mapped to UniProt Q99705. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL344
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q99705
Melanin-concentrating hormone receptor 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Melanin-concentrating hormone receptor 1 matters
Melanin-concentrating hormone receptor 1 is reviewed as Melanin-concentrating hormone receptor 1 (UniProt Q99705); the current evidence base includes 0 approved drugs, 4217 compounds, and 262 assays, with lead potency reaching pChEMBL 10.5.
Protein context
Melanin-concentrating hormone receptor 1
Melanin-concentrating hormone receptor 1 Sequence length is 353 aa.
Review this target as Melanin-concentrating hormone receptor 1, mapped to UniProt Q99705. Sequence length is 353 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q99705
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 4217 compounds, and 262 assays for this target. The dominant activity type is IC50. CHEMBL557629 is the current potency anchor at pChEMBL 10.5.
Use CHEMBL557629 as the tractability anchor when discussing potency (pChEMBL 10.5).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 10.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Melanin-concentrating hormone receptor 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q99705, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4217
Total Compounds
262
Total Assays
0
Approved Drugs
IC50: 3468.0, KI: 1869.0, EC50: 83.0, KD: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL557629
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL468099
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL250516
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL214322
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL568571
|
9.9 | IC50 | — |
Source Header